NetworkNewsBreaks

MondayFeb 06, 2017 1:14 pm

NetworkNewsBreaks – Accuray, Inc. (NASDAQ: ARAY) Covered at Aegis Capital with ‘Buy’ Rating, $7 PT

Aegis Capital Corp. has initiated coverage of Accuray (NASDAQ: ARAY), issuing a 'Buy' rating and $7 price target on the company's stock. Accuray is a radiation oncology company with distinctive, innovative products specifically designed for image-guided radiosurgery and intensity-modulated radiation therapy - two rapidly growing market segments. The company’s most recent financial results, for the second fiscal quarter and six months ended December 31, 2016, show second-quarter gross orders of $78.5 million with net orders of $54.1 million totaling year-over-year growth of 17%, as well as an ending backlog increase of 16% year-over-year to $426.2 million. To learn more, visit…

Continue Reading

MondayFeb 06, 2017 12:03 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on February 6, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ETST 29.63% – News: Announces new wholly owned subsidiary, Cannabis Therapeutics, Inc. HTCO 24.10% – News: Accumulates close to $12M in prospective sales for its "grow.droid" platform FNBC 15.13% – News: Appoints new CEO NWBO 12.47% – News: Provides an update on phase III trial of DCVax®-L SIRC 12.32% – News: Supports the non-profit organization GRID Alternatives JTPY 11.07% – News: Enters agreement with the Office of the Illinois State Treasurer to become the…

Continue Reading

MondayFeb 06, 2017 12:02 pm

NetworkNewsBreaks – Recon Technology (NASDAQ: RCON) Receives Authorization to Bid on Future ABB (NYSE: ABB) Projects

Recon Technology (NASDAQ: RCON) this morning announced it has received an authorization letter from ABB (NYSE: ABB), enabling Recon to bid on several of the power and automation technology company’s upcoming projects. Recon said it would provide on-site project commissioning and maintenance services to ABB for any successful project bids. "We are pleased to receive authorization from ABB, giving Recon recognition from the global pioneer of automation technology. Over the years, we have been committed to the exploration and development of new business opportunities outside our traditional oilfield sector. We are confident that our experience within the energy industry, as…

Continue Reading

MondayFeb 06, 2017 12:00 pm

NetworkNewsBreaks – Ocean Power Technologies, Inc. (NASDAQ: OPTT) Inks Development and Marketing Agreement with HAI Technologies; Shares Surge

Ocean Power Technologies (NASDAQ: OPTT) (“OPT”) and HAI Technologies Corp. this morning announced they will seek mutual opportunities through a joint applications development and marketing agreement, initially concentrating on offshore oil and gas subsea chemical injection systems. Under the agreement, HAI Technologies’ advanced chemical injection solutions will be combined with OPT’s PB3 PowerBuoy® to generate new methods for long distance and remote offshore field developments. Shares of OPT are up 14% following the news. “We are excited to join efforts with such an innovative company as HAI Technologies. Chemical injection systems require persistent and reliable power, and we believe OPT’s…

Continue Reading

MondayFeb 06, 2017 11:20 am

NetworkNewsBreaks – FDA Grants Small Business Status to Cytori (NASDAQ: CYTX)

Cytori (NASDAQ: CYTX) has been granted Small Business status for fiscal year 2017 by the U.S. Food and Drug Administration Division of Industry and Consumer Education. The designation allows Cytori to receive substantial financial incentives, fee reductions, and fee waivers for selective FDA medical device regulatory filings. The company is also eligible for a substantial reduction in many medical device user fees and a one-time waiver of the user fee for its first premarket approval (PMA) application, potentially occurring later in 2017. “Cytori Cell Therapy benefits from being regulated as a device through the PMA process. The small business designation…

Continue Reading

MondayFeb 06, 2017 11:15 am

NetworkNewsBreaks – Rosetta Genomics (NASDAQ: ROSG) Receives Two U.S. Patent Allowances for RosettaGx Reveal™ microRNAs

Rosetta Genomics (NASDAQ: ROSG) shares are nudging higher after the company said the U.S. Patents and Trademark Office has granted two patent allowances for divisional patents of the parent application titled “microRNAs and uses thereof.” The company said the patents are important markers for its RosettaGX Reveal™ thyroid cancer assay, as this strengthens its intellectual property portfolio and provides opportunities for monetization. “We are creating a strong intellectual property position in microRNAs and thyroid cancer diagnostics. Of note, there are approximately 500 peer-reviewed publications that confirm the effectiveness of microRNAs as biomarkers in the diagnosis of thyroid cancer which makes…

Continue Reading

FridayFeb 03, 2017 3:46 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on February 3, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: AMRS 14.15% – News: Provides highlights of operational and financial results SRAX 6.44% - Appoints private equity investor Derek Ferguson to board of directors and audit committee TGTX 6.52% – News: Law firm files a securities class action lawsuit RWLK 5.95% – News: Law firm announces the filing of a class action lawsuit FNMA 3.08% – News: Announces delisting date from Euro MTF market of the Luxembourg Stock Exchange EARS 2.56% – News: Expands…

Continue Reading

FridayFeb 03, 2017 3:44 pm

NetworkNewsBreaks – Soligenix, Inc.’s (NASDAQ: SNGX) SGX301 Receives Promising Innovative Medicine Designation in the UK; Aegis Capital Increases PT to $7

Shares of Soligenix (NASDAQ: SNGX) continued to climb Friday following the company’s announcement yesterday that its SGX301 was granted Promising Innovative Medicine (PIM) designation in the United Kingdom by the Medicines and Healthcare Products Regulatory Agency for the treatment of cutaneous T-cell lymphoma. The PIM designation is the first step toward inclusion in the Early Access to Medicines Scheme (EAMS), which provides severely ill patients with life-threatening and seriously debilitating conditions early access to groundbreaking new medicines - before marketing authorization is approved. "This is now the second of our programs to receive this important designation, with the first being…

Continue Reading

FridayFeb 03, 2017 12:22 pm

NetworkNewsBreaks – Amyris, Inc. (NASDAQ: AMRS) Shares Spike 13% on Corporate and Financial Update

Shares of Amyris (NASDAQ: AMRS) are higher after the bioscience company issued an update on certain aspects of its business and financial results for 2016. Amyris reported three key updates: record revenue in both collaborations and product sales for 2016; near-term debt maturities resolved; and the completion of strategic transition out of commodity products. “We are pleased to have achieved a record year of revenue growth, and of having completed all of the 2016 strategic milestones we set out to, and we continue to make good progress on our debt structure by having resolved our near-term debt maturity issues in…

Continue Reading

FridayFeb 03, 2017 12:18 pm

NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) Prices $3.6M Public Offering; Shares Tumble

Shares of Interpace Diagnostics Group (NASDAQ: IDXG) are 25% lower in late morning trade after the company priced its public offering of 1.2 million shares of common stock at $3 per share for estimated gross proceeds of approximately $3.6 million. Additionally, the company has permitted the representative of the underwriters an over-allotment option to purchase up to an additional 108,000 shares of its common stock. Interpace said it intends to use the net proceeds of the offering for working capital, repayment of debt and other liabilities, and general corporate purposes. Pending customary closing conditions, the offering is expected to close…

Continue Reading